## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.7% below STRENGTH zone (3.0-6.0%); PEG 3.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($569.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. The Truth About Intuitive Surgical Inc: Why Everyone Is Betting On Robot Surgeons**
- Source: AD HOC NEWS | 20260104T040819 | Bullish | Relevance: 100%
- This article analyzes Intuitive Surgical Inc. (ISRG), maker of the da Vinci robotic surgical system, to determine if its high valuation is justified or mere hype. It highlights the company's strong market position due to its "razor-and-blades" business model, established user base, and continuous expansion into new procedures, contrasting it with competitors like Medtronic and Johnson & Johnson. The piece concludes that ISRG is a high-conviction play for investors betting on the future of healthcare technology, despite its premium price.

**2. Intuitive Surgical, Inc. $ISRG Shares Sold by Greenleaf Trust**
- Source: MarketBeat | 20260106T130809 | Somewhat-Bullish | Relevance: 100%
- Greenleaf Trust significantly reduced its stake in Intuitive Surgical (ISRG) by 43.4% in Q3, selling 8,798 shares. This comes despite major institutional investors like Vanguard and Norges Bank increasing their positions, and Intuitive Surgical exceeding revenue and EPS expectations. Insider selling also saw 114,007 shares sold last quarter, totaling over $63 million.

**3. Hennion & Walsh Asset Management Inc. Cuts Stock Position in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20260106T122814 | Neutral | Relevance: 100%
- Hennion & Walsh Asset Management Inc. significantly reduced its stake in Intuitive Surgical, Inc. (ISRG) by 13.9% in the third quarter of 2025, selling 2,207 shares and holding 13,638 shares valued at $6.10 million. Concurrently, company insiders have sold 114,007 shares totaling $63.53 million in the past three months, notably CEO Gary S. Guthart decreasing his ownership by nearly 90%. Despite these sales, analysts generally maintain a "Moderate Buy" rating for ISRG with an average price target of $612.75, showing continued optimism for the medical equipment provider.

**4. The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson**
- Source: The Globe and Mail | 20260106T110823 | Bullish | Relevance: 100%
- This Zacks Analyst Blog highlights five medical-sector stocks, Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals, and Johnson & Johnson, that are leveraging Artificial Intelligence (AI) to drive growth and innovation. The article discusses how AI is transforming diagnostics, treatment, and operational efficiency within the healthcare industry and provides financial insights and strategic applications of AI for each company. These companies are identified as potential high-growth providers due to their extensive use of AI.

**5. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026**
- Source: The Globe and Mail | 20260105T140818 | Somewhat-Bullish | Relevance: 100%
- This article highlights five AI-powered medical stocks – Eli Lilly (LLY), Medtronic (MDT), Intuitive Surgical (ISRG), Regeneron Pharmaceuticals (REGN), and Johnson & Johnson (JNJ) – for a strong portfolio in 2026. It details how AI has reshaped the medical landscape by revolutionizing diagnostics, treatment, and operational efficiency. Each company's integration of AI into their products, pipeline, and operations is discussed, along with their financial performance and Zacks Ranks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.48 signals overvaluation risk, limited margin of safety. Forward P/E 60.8x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $212.5B |
| Beta | 1.67 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.48 |
| Forward P/E | 60.8 |
| Current P/E | 68.6 |
| YoY Growth | 12.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -0.1% to 2.7% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.3pp (needs >3.0% for momentum thesis). MRS_5 at 2.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +FTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.73% (CS: 69) | Neutral |
| RSI_14 | 65.5 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.157x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $592.85
- **Stop Loss:** $569.91 (3.9% risk)
- **Target:** $615.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $33,792.45
- **Portfolio %:** 33.79%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*